At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 4,744 enrolled
Drug / intervention
Dapagliflozin +1 moredrug
Likely dose
Dapagliflozin 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure With Reduced Ejection Fraction
In Brief
A Phase 3 clinical trial evaluating Dapagliflozin and Placebo for Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). Completed, enrolled 4,744 participants across 419 sites in 20 countries.
Detailed Summary
The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Brazil, Bulgaria, Canada, China, Czechia, Denmark, Germany, Hungary, India, Japan, Netherlands, Poland, Russia, Slovakia, Sweden, Taiwan, United Kingdom, United States, Vietnam
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 2017
Enrollment StartFeb 2017
Primary CompletionJul 2019
TodayJul 2026
First PostedJan 30, 2017
Enrollment StartFeb 8, 2017
Primary CompletionJul 17, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 9.4 years ago
Interventions
Dapagliflozindrug
10 mg or 5 mg tablets given once daily, per oral use.
Placebodrug
Placebo matching dapagliflozin 10 mg or 5 mg.